The FDA’s rejection of MDMA as a treatment may well be a short-term setback for legally helping people with PTSD and other disorders. Mason Marks of Harvard Law School’s Petrie-Flom Center for Health Law Policy offers his assessment.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.